Abstract | BACKGROUND: MATERIALS AND METHODS: From January 1999 to February 2002, 295 patients were randomized to receive either IRI/LV/5-FU or OXA/LV/5-FU. The treatment schedules consisted of weekly IRI 70 mg/m(2) or OXA 45 mg/m(2) plus LV 200 mg/m(2) followed immediately by intravenous bolus 5-FU 450 mg/m(2) for 6 weeks, followed by a 2-week rest period. Treatment was continued for up to four cycles or until disease progression, unacceptable toxicity or patient refusal. RESULTS: There were no significant differences between the study arms in the overall response rate (33% with IRI/LV/5-FU versus 32% with OXA/LV/5-FU based on responses demonstrated on a single evaluation; 23% with IRI/LV/5-FU versus 22.3% with OXA/LV/5-FU based on responses confirmed according to WHO criteria) median time to progression (8.9 versus 7.6 months), and median overall survival (17.6 versus 17.4 months). Toxicity profiles (grades 3 and 4) were similar in the IRI and OXA arms ( diarrhea 12.3% and 9.8%, neutropenia 8.2% and 4.9%, and febrile neutropenia 1.4% and 1.4%, respectively), with the exception of grade 3 sensory neuropathy, which almost exclusively occurred in the OXA arm (0% versus 5.6%; P=0.003, Fisher's exact test). CONCLUSION: The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA-LV/5-FU.
|
Authors | H P Kalofonos, G Aravantinos, P Kosmidis, P Papakostas, T Economopoulos, M Dimopoulos, D Skarlos, A Bamias, D Pectasides, S Chalkidou, M Karina, A Koutras, E Samantas, C Bacoyiannis, G F Samelis, G Basdanis, F Kalfarentzos, G Fountzilas |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 16
Issue 6
Pg. 869-77
(Jun 2005)
ISSN: 0923-7534 [Print] England |
PMID | 15855226
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Organoplatinum Compounds
- Oxaliplatin
- Irinotecan
- Leucovorin
- Fluorouracil
- Camptothecin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Colorectal Neoplasms
(drug therapy, mortality)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Irinotecan
- Leucovorin
(administration & dosage)
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
|